Vivet Therapeutics SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vivet Therapeutics SAS - overview
Established
2016
Location
Paris, -, France
Primary Industry
Biotechnology
About
Founded in 2016 and based in Paris, France, Vivet Therapeutics SAS operates as a developer of gene therapy treatments for orphan diseases. The company was founded by its CEO, Jean-Philippe Combal, and CSO, Gloria Gonzalez-Aseguinolaza. In February 2024, Vivet Therapeutics raised EUR 4. 9 million in grant funding from France 2030.
Vivet Therapeutics develops gene therapies and orphan drugs for rare inherited metabolic disorders. The firm’s gene therapy product, VTX-806, is an (adeno-associated virus) AAV-based gene therapy for cerebrotendinous xanthomatosis (CTX). The company plans to use the funds raised in February 2024 to support the development of its gene therapy product called VTX-806.
Current Investors
HealthCap, Novartis Venture Fund, Eurazeo
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.vivet-therapeutics.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.